CCR7 and metastatic malignant neoplasm in the lymph nodes: The CCR7(+) patients exhibited a significantly higher rate of lymph node metastasis (p = 0.037) and a poor five-year overall survival (OS, 53.2% versus 25.0%, p = 0.013) (Figure 1b).